We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.13 | 0.09% | 151.31 | 2,175 | 12:07:54 |
From May 2019 to May 2024
By Josh Beckerman
Johnson & Johnson's Janssen Pharmaceutical Cos. unit will work with the U.S. Department of Health and Human Services to accelerate development of a potential novel coronavirus vaccine.
An expanded collaboration with the Biomedical Advanced Research and Development Authority "builds on Johnson & Johnson's multipronged response" to the coronavirus outbreak, the company said.
The company is "working closely with global partners to screen its library of antiviral molecules to accelerate the discovery of potential COVID-19 treatments."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 11, 2020 17:09 ET (22:09 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
